CoronaryAtlas logo
CoronaryAtlas
Uric acid
Pathway / Plaque inflammation

Uric acid

metabolite

Uric acid accumulates during oxidative injury and endothelial dysfunction in acute MI, serving as a biomarker of inflammatory burden and CAD severity.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleOxidative stress and inflammation marker; endothelial dysfunction driver; elevated in ACS; links hyperuricemia to MI and coronary pathology.
Also acts inEndothelial activation/erosion, Lipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
50
A — assay feasibility
84
E — evidence strength
39
T1DI (composite)
11
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 1
4bstent thrombosismag 1
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
Enzymatic (uricase)
Reagent / substrate
Uricase → allantoin + H2O2; peroxidase Trinder, read 550 nm
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(8)